Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 versus placebo for chronic peripheral neuropathic pain
2022-501461-52-00Phase 2Completed
- Sponsor
- Merz
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Peripheral neuropathic pain, postherpetic neuralgia (PHN) and Neuralgia comparing NT 201 / Xeomin with Placebo (2 arms). Primary endpoint: Weekly averages of changes from baseline in average daily pain intensity at Weeks 2 to 12. Started Oct 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Peripheral neuropathic painpostherpetic neuralgia (PHN)Neuralgia
Beyond the preview
Go deeper on 2022-501461-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501461-52-00.